Lacosamide Eg (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, stabilizing hyperexcitable neuronal membranes. This action reduces the likelihood of repetitive neuronal firing that underlies seizure activity, without significantly affecting normal neuronal signaling.

The specific dose of Lacosamide Eg is determined by the prescribing clinician based on the individual’s medical condition, age, renal and hepatic function, and response to therapy. Patients should follow the dosage instructions provided by their healthcare professional.

The safety of lacosamide in pregnancy and lactation has not been fully established. It should be prescribed only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Lacosamide’s unique mechanism—enhancing slow sodium‑channel inactivation—differs from many traditional antiepileptics that target fast inactivation. This can offer an alternative for patients who have inadequate response or intolerable side effects with other agents, while maintaining a comparable efficacy profile for focal seizures.

Lacosamide Eg should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Lacosamide Eg is administered orally, typically as a tablet taken with or without food. The exact dosing schedule—once or twice daily—depends on the prescriber’s instructions and the patient’s therapeutic needs.

Serious risks include the potential for suicidal thoughts or behavior, cardiac conduction abnormalities such as PR‑interval prolongation, and rare severe skin reactions like Stevens‑Johnson syndrome. Patients should promptly report any mood changes, chest discomfort, or skin eruptions to their healthcare provider.

Lacosamide Eg is contraindicated in individuals with known hypersensitivity to lacosamide or any of its excipients. Patients with significant cardiac conduction disorders, uncontrolled arrhythmias, or those taking medications that markedly prolong the PR interval should avoid its use unless closely monitored.